NEWS : Genovior Biotech Collaboration Expands into the US Market, Signs Product Licensing Agreement to Expand Its Portfolio of Fully Synthetic Peptide Pharmaceuticals

Taipei, July 24 , 2025 – Genovior Biotech Collaboration (hereinafter referred to as “Genovior”) announced today that it has signed an exclusive product licensing and collaboration agreement with a US pharmaceutical company, officially launching its business layout in the US market.

According to the agreement, Genovior partner will be granted product authorization, trademark, marketing authorization for the prescription drug in the US market and the right to obtain supply cooperation with a new factory in Taiwan to support high demand needs such as chronic diseases and special dosage form manufacturing.
This portfolio generated total US sales of $ 650 million in 2022 and has demonstrated a 5 % compound annual growth rate over the past three years, highlighting its continued growth potential in emerging markets. Both parties anticipate completing the submission process in the second quarter of 2026, and Genovior will initiate subsequent drug license maintenance and local commercial development initiatives. Under the terms of the agreement, Genovior will receive up to several million US dollars in upfront and milestone payments, as well as double-digit tiered royalties in this market.
Dr. Steve Hsu, Chairman of Genovior Biotech Collaboration said:
"We are honored to collaborate with this leading American pharmaceutical company to further introduce Genovior 's fully synthetic peptides and specialty injectable formulations into the local market. This licensing agreement not only lays the foundation for further expansion into the US market, but also demonstrates our global business approach, centered on technology integration and guided by regional strategies."
He added:
" Genovior will extensive GMP compliance experience in multiple countries, including the EU EMA and Japan's Ministry of Health , Labor and Welfare. We are also one of the few companies in Asia with a fully synthetic peptide platform and sterile injectable filling capabilities. We are confident in providing a stable, safe, and world-class supply of pharmaceuticals to the US market."

About Genovior Biotech Collaboration

Genovior is an innovative pharmaceutical company specializing in the development of peptide active pharmaceutical ingredients (APIs) and formulations. Leveraging its proprietary fully synthetic peptide technology platform and sterile injectable formulation process, Genovior is committed to providing high-quality, highly stable, and internationally compliant pharmaceuticals and contract manufacturing services. Genovior 's products and services cover a wide range of therapeutic areas, including hypoglycemics, weight management, oncology, psychiatry, and critical care. Genovior has successfully expanded its product offerings into the European and Asian markets and continues to advance its global presence and internationalize its brand through strategic partnerships, drug licensing, and contract development and manufacturing.